Hepatorenal Syndrome: Update on Diagnosis and Treatment

Overview

Journal World J Nephrol

Publisher Baishideng Publishing Group

Specialty Nephrology

Date 2015 Nov 12

PMID 26558188

Citations 15

Authors

Olga Baraldi

Chiara Valentini

Gabriele Donati

Giorgia Comai

Vania Cuna

Irene Capelli

Maria Laura Angelini

Maria Ilaria Moretti

Andrea Angeletti

Fabio Piscaglia

Gaetano La Manna

Affiliations

Soon will be listed here.

Abstract

Acute kidney injury (AKI) is a common complication in patients with end-stage liver disease and advanced cirrhosis regardless of the underlying cause. Hepatorenal syndrome (HRS), a functional form of kidney failure, is one of the many possible causes of AKI. HRS is potentially reversible but involves highly complex pathogenetic mechanisms and equally complex clinical and therapeutic management. Once HRS has developed, it has a very poor prognosis. This review focuses on the diagnostic approach to HRS and discusses the therapeutic protocols currently adopted in clinical practice.

Citing Articles

Addition of a Loop Diuretic to Norepinephrine During Treatment of Hepatorenal Syndrome Type 1.

Velez J, Wickman T, Tayebi K, Mohamed M, Yousuf A, Kanduri S Kidney Int Rep. 2025; 10(2):466-474.

PMID: 39990915 PMC: 11843126. DOI: 10.1016/j.ekir.2024.11.013.

Real-world comparison of terlipressin vs. octreotide as an adjuvant treatment in the management of variceal bleeding.

Rehman H, Rehman S, Zulfiqar S, Awan S, Abid S Sci Rep. 2024; 14(1):6692.

PMID: 38509184 PMC: 10954665. DOI: 10.1038/s41598-024-56873-x.

A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug.

Thangaraj S, Srinivasan M, Arzoun H, Thomas S Cureus. 2023; 15(7):e42367.

PMID: 37621788 PMC: 10445509. DOI: 10.7759/cureus.42367.

Adaptive Mechanisms of Renal Bile Acid Transporters in a Rat Model of Carbon Tetrachloride-Induced Liver Cirrhosis.

Donadei C, Angeletti A, Cappuccilli M, Conti M, Conte D, Zappulo F J Clin Med. 2022; 11(3).

PMID: 35160088 PMC: 8836491. DOI: 10.3390/jcm11030636.

Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome.

Sangroongruangsri S, Kittrongsiri K, Charatcharoenwitthaya P, Sobhonslidsuk A, Chaikledkaew U Clinicoecon Outcomes Res. 2021; 13:703-715.

PMID: 34349534 PMC: 8328389. DOI: 10.2147/CEOR.S317390.

References

Banares R, Nevens F, Larsen F, Jalan R, Albillos A, Dollinger M . Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2012; 57(3):1153-62. DOI: 10.1002/hep.26185. View

. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010; 53(3):397-417. DOI: 10.1016/j.jhep.2010.05.004. View

Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O . Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000; 119(6):1637-48. DOI: 10.1053/gast.2000.20189. View

Koppel M, Coburn J, MIMS M, Goldstein H, Boyle J, RUBINI M . Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease. N Engl J Med. 1969; 280(25):1367-71. DOI: 10.1056/NEJM196906192802501. View

Sharawey M, Shawky E, Ali L, Mohammed A, Hassan H, Fouad Y . Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis. Hepatol Int. 2011; 5(4):927-33. DOI: 10.1007/s12072-011-9266-y. View

Marik P, Gayowski T, Starzl T . The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med. 2005; 33(6):1254-9. PMC: 2989684. DOI: 10.1097/01.ccm.0000164541.12106.57. View

Witzke O, Baumann M, Patschan D, Patschan S, Mitchell A, Treichel U . Which patients benefit from hemodialysis therapy in hepatorenal syndrome?. J Gastroenterol Hepatol. 2004; 19(12):1369-73. DOI: 10.1111/j.1440-1746.2004.03471.x. View

Gines P, Guevara M, Arroyo V, Rodes J . Hepatorenal syndrome. Lancet. 2003; 362(9398):1819-27. DOI: 10.1016/S0140-6736(03)14903-3. View

Angeli P, Gines P . Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice. J Hepatol. 2012; 57(5):1135-40. DOI: 10.1016/j.jhep.2012.06.024. View

10.

Nadim M, Kellum J, Davenport A, Wong F, Davis C, Pannu N . Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2012; 16(1):R23. PMC: 3396267. DOI: 10.1186/cc11188. View

11.

Fabrizi F, Dixit V, MARTIN P . Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther. 2006; 24(6):935-44. DOI: 10.1111/j.1365-2036.2006.03086.x. View

12.

Gerbes A, Gulberg V, Waggershauser T, Holl J, Reiser M . Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology. 1998; 28(3):683-8. DOI: 10.1002/hep.510280313. View

13.

Seo Y, Jung E, An H, Kim J, Jung Y, Kim J . Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Liver Int. 2009; 29(10):1521-7. DOI: 10.1111/j.1478-3231.2009.02105.x. View

14.

Liangpunsakul S, Agarwal R . Renal failure in cirrhosis: is it time to change the diagnosis and classification?. Am J Nephrol. 2013; 38(4):342-4. PMC: 3877928. DOI: 10.1159/000355570. View

15.

Wilkinson S, Weston M, Parsons V, Williams R . Dialysis in the treatment of renal failure in patients with liver disease. Clin Nephrol. 1977; 8(1):287-92. View

16.

Fagundes C, Pepin M, Guevara M, Barreto R, Casals G, Sola E . Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol. 2012; 57(2):267-73. DOI: 10.1016/j.jhep.2012.03.015. View

17.

Fede G, DAmico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D . Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2011; 56(4):810-8. DOI: 10.1016/j.jhep.2011.10.016. View

18.

Arroyo V, Colmenero J . Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003; 38 Suppl 1:S69-89. DOI: 10.1016/s0168-8278(03)00007-2. View

19.

Mocarzel L, Lanzieri P, Nascimento J, Peixoto C, Ribeiro M, Mesquita E . Hepatorenal syndrome with cirrhotic cardiomyopathy: case report and literature review. Case Reports Hepatol. 2015; 2015:573513. PMC: 4385646. DOI: 10.1155/2015/573513. View

20.

Gonwa T, Mai M, Melton L, Hays S, Goldstein R, Levy M . Renal replacement therapy and orthotopic liver transplantation: the role of continuous veno-venous hemodialysis. Transplantation. 2001; 71(10):1424-8. DOI: 10.1097/00007890-200105270-00012. View